Skip to content

Paravertebral Block for Postoperative Analgesia in Thoracoscopic Surgery

Patient Controlled Paravertebral Analgesia for Video-assisted Thoracoscopic Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03242668
Enrollment
30
Registered
2017-08-08
Start date
2016-06-01
Completion date
2017-07-01
Last updated
2017-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

paravertebral block,PVC,PCA

Brief summary

To access the analgesic efficacy of patient controlled thoracic paravertebral analgesia.

Detailed description

The study was carried out on thirty patients who underwent video-assisted thoracic surgery.Paravertebral space was identified by loss of resistance technique under video-assisted inside thoracic space before chest close.Initiated dose of 0.3ml/kg of bupivacaine 0.125%+fentanyl 2 mcg/ml was administered then continued patient-controlled analgesia with background rate 3ml/h, bolus dose 2ml, lockout interval 10 minutes. Postoperative pain was accessed by Visual Analogue Scale at rest and on coughing; monitor the heart rate, blood pressure, respiratory rate, SpO2, arterial blood gas and spirometry in three postoperative consecutive days.

Interventions

PROCEDUREVATS

General anesthesia was induced with 2.0 mg/kg of propofol, 2.0 mg/kg of fentanyl, and 1.0 mg kg/1 of rocuronium and maintained with continuous infusion 6-12mg/kg/h of propofol,injected 2.0 mg/kg of fentanyl and 0.15 mg/ kg of rocuronium every 30 minutes . All patients were intubated with a double-lumen endobronchial tube for one-lung ventilation.The VATS (Video-Assisted Thoracic Surgery) was performed.

PROCEDUREPVB using PVC

At the end of the surgery, the upper edge of the spinous process of the thoracic vertebral body was recognized. With an epidural needle (Tuohy 22 G; Braun, Melsungen, Germany), the injection point was punctured 2 cm lateral to the midline. The paravertebral space was entered by advancing the Tuohy needle over the superior border of the transverse process. Once in the right place, the PVC was placed through the needle, checking the tip remained placed when removing the needle. The advance of the needle and the entering of the catheter into the paravertebral space were verified all the time by the surgeon using the camera. The PVC (Paravertebral Catheter ) was inserted at this point preversed at this area.

DRUGPCA

PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA (Perfusor space pump,Germany)with background rate 3ml/h, bolus dose 2ml was infused through PVC.

Sponsors

Nguyen Truong Giang, PhD. Associate Prof.
CollaboratorUNKNOWN
Nguyen Trung Kien
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

30 patients, with American Society of Anesthesiologists class I to III risk undergoing elective VATS, aged 32-72 years, scheduled for lung resection surgery , were enrolled in this randomised observer blinded prospective clinical study. Patients who refused to participate, less than 18 years of age, ASA physical status 3 or more, allergy to any of the study drugs, patients having any contraindication for paravertebral block, kyphoscoliosis, presence of acute herpes zoster, chronic pain syndrome, chronic analgesic use and psychiatric disease were excluded from this study.

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiologists class I to III risk undergoing elective VATS, aged 32-72 years, scheduled for lung resection surgery.

Exclusion criteria

* Patients who refused to participate, less than 18 years of age, ASA physical status 3 or more,, allergy to any of the study drugs, patients having any contraindication to placement of PVB, kyphoscoliosis, presence of acute herpes zoster, chronic pain syndrome, chronic analgesic use and psychiatric disease.

Design outcomes

Primary

MeasureTime frameDescription
VAS score at rest and on coughing72 hoursUsing VAS scale (Atrazennica)

Secondary

MeasureTime frameDescription
Arterial blood gas valuesthree postoperative consecutive daysUsing Arterial blood gas analysis (STAT Model No.MCP9819-065, Martel Instruments Ltd)
The number dermatome inhibitionthree postoperative consecutive daysUsing pin-prick test
Rescue analgesiathree postoperative consecutive daysWhen VAS score equal to or more than 4 using fentanyl to manage pain
Patient's satisfactionthree postoperative consecutive daysUsing questionaire with 4 levels :not good,satisfied,good,very good
Analgesia effects on respiratory functionthree postoperative consecutive daysUsing Spirometry (Chestgraph H1 - 105,Japane) to evaluate respiratory index

Other

MeasureTime frameDescription
Blood pressurethree postoperative consecutive daysUsing monitoring (Philips)
Heart ratethree postoperative consecutive daysUsing monitoring (Philips)
Side effects and complicationsthree postoperative consecutive daysRespiratory depression (respiratory rate \< 8 breaths/min), ,confusion, sedation, urinary retention, nausea, vomiting, headache and pruritus was evaluated.

Countries

Vietnam

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026